P
Paul Catchpole
Researcher at Association of the British Pharmaceutical Industry
Publications - 3
Citations - 629
Paul Catchpole is an academic researcher from Association of the British Pharmaceutical Industry. The author has contributed to research in topics: Nice & Health economics. The author has an hindex of 2, co-authored 3 publications receiving 583 citations.
Papers
More filters
Journal ArticleDOI
Delivering affordable cancer care in high-income countries
Richard Sullivan,Jeffrey Peppercorn,Karol Sikora,John Zalcberg,Neal J. Meropol,Eitan Amir,David Khayat,Peter Boyle,Philippe Autier,Ian F. Tannock,Tito Fojo,Jim Siderov,Steve Williamson,Silvia Camporesi,J. Gordon McVie,Arnie Purushotham,Peter Naredi,Alexander M.M. Eggermont,Murray F. Brennan,Michael L. Steinberg,Mark De Ridder,Susan A. McCloskey,Dirk Verellen,Terence Roberts,Guy Storme,Rodney J. Hicks,Peter J. Ell,Bradford R. Hirsch,David P. Carbone,Kevin A. Schulman,Paul Catchpole,David Taylor,Jan Geissler,Nancy G Brinker,David O. Meltzer,David J. Kerr,Matti Aapro +36 more
TL;DR: Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system.
Journal ArticleDOI
Keeping Pace with Pharmaceutical Innovation: The Importance of the NICE Methods Review.
Paul Catchpole,Victoria Barrett +1 more
TL;DR: NICE’s methods review provides a timely opportunity to make the changes needed to ensure their value is comprehensively captured, so that patients can access the latest treatments.
Journal ArticleDOI
Analysis of the impact of extending end of life treatments should be treated with caution.
TL;DR: This study shows how NICE’s cost effectiveness threshold should work in terms of determining whether supplementary advice on life extending end of life treatments introduced by NICE in 2009 is effective.